As of Feb 21, 2025, United Therapeutics Corporation Intrinsic Value is $406.0. This suggests it may be undervalued by 12.4% compared to its current price of around $361.1.
As of Feb 21, 2025, United Therapeutics Corporation's Discounted Cash Flow (DCF) valuation estimates its share price at $440.2. This suggests it may be overvalued by 21.9% to its current price of around $361.1, using a discount rate of 7.5% and terminal growth rate of 3.0%.
United Therapeutics Corporation is currently considered undervalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $406.0, compared to a market price of around $361.1. This suggests a potential undervaluation of 12.4%.